🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 59 of 857 · Phase 3 first, then by program name

  1. ELX/TEZ/IVA

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    19 trials

  2. EMB-Fatol® 100 mg, Tabletten, The placebo for Amikacin Liposome for Inhalation Suspension drug product is a white translucent suspension consisting of dipalmitoylphosphatidylcholine (DPPC) and cholesterol, which are dispersed in 1.5% (w/w) sodium chloride solution. The placebo is filled into the same container closure system of the drug product, Azithromycin-ratiopharm 250mg Filmtabletten, Azithromycin STADA® 250 mg Filmtabletten, Azithromycin AL 250 mg Filmtabletten, Azitromicina Teva 250 mg comprimidos re

    Insmed Limited

    "Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)"

    phase 3 small molecule active

    1 trial

  3. EMPAGLIFLOZIN , DAPAGLIFLOZIN , INSULIN GLARGINE , Placebo to match LY3502970, METFORMIN

    Eli Lilly Co.

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  4. EMPAGLIFLOZIN, BI 690517, Placebo matching vicadrostat

    Boehringer Ingelheim

    Heart failure

    phase 3 small molecule active

    1 trial

  5. EMPAGLIFLOZIN, Placebo matching BI 690517, BI 690517

    Boehringer Ingelheim

    Heart failure (HF)

    phase 3 small molecule active

    1 trial

  6. EMTRICITABINE, TENOFOVIR ALAFENAMIDE AND BICTEGRAVIR, Placebo to BIK/FTC/TAF, islatravir, ulonivirine, MK-8591B, Placebo to 8591B

    Merck Sharp and Dohme

    HIV

    phase 3 small molecule active

    1 trial

  7. ENCORAFENIB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Binimetinib placebo, BINIMETINIB, Encorafenib Pacebo

    Pfizer Australia Pty Ltd

    Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanoma

    phase 3 small molecule active

    1 trial

  8. ENOXAPARIN

    Pari Pharma GmbH

    Allograft vascular thrombosis

    phase 3 small molecule active

    1 trial

  9. ENTECAVIR , VAY736, Placebo to VAY736 300 mg/2 mL Solution for injection in pre-filled syringe, Placebo to VAY736 300 mg/2 mL Solution for injection in pre-filled pen, TENOFOVIR ALAFENAMIDE , -, VAY736, TENOFOVIR DISOPROXIL

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  10. EPREX®

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Renal Anemia

    phase 3 small molecule completed

    1 trial

  11. ERIBULIN MESYLATE, VINORELBINE, GEMCITABINE, CAPECITABINE, CAPECITABINE, Datopotamab deruxtecan

    AstraZeneca AB

    "Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer that Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy"

    phase 3 small molecule active

    1 trial

  12. ERYTHROPOIETIN , Elritercept

    Takeda

    Myelodysplastic neoplasms/syndromes (MDS)

    phase 3 small molecule active

    1 trial

  13. ESTREVA 0,1 %, gel, ANDROGEL 16,2 mg/g, gel, PROVAMES 1 mg, comprimé pelliculé

    Pari Pharma GmbH

    gender dysphoria

    phase 3 small molecule active

    1 trial

  14. ETC-1002

    Esperion Therapeutics

    Hypercholesterolemia

    phase 3 small molecule completed

    6 trials

  15. ETEPLIRSEN (AVI-4658)

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 small molecule active

    1 trial

  16. ETIDRONATE DISODIUM ORAL CAPSULES 400 MG

    Disc Medicine

    Pseudoxanthoma Elasticum

    phase 3 small molecule active

    1 trial

  17. ETOPOSIDE

    Pari Pharma GmbH

    Hemophagocytic lymphohistiocytosis (HLH)

    phase 3 small molecule active

    1 trial

  18. ETOPOSIDE , DEXAMETHASONE

    Pari Pharma GmbH

    Hemophagocytic lymphohistiocytosis (HLH)

    phase 3 small molecule active

    1 trial

  19. ETOPOSIDE - Usual

    Lxo Ireland Designated Activity Company

    Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  20. ETOPOSIDE, ATEZOLIZUMAB, PF-08634404, CARBOPLATIN

    Pfizer Australia Pty Ltd

    Extensive-Stage Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  21. ETOPOSIDE, Atigotatug + Nivolumab FDC, CARBOPLATIN, ATEZOLIZUMAB

    Bristol-Myers Squibb Australia Pty Ltd

    Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  22. ETOPOSIDE, PACLITAXEL, IFOSFAMIDE, CISPLATIN, CARBOPLATIN

    Ningbo Cancer Hospital

    Progressive or recurrent germ cell tumor (measurable or non-measurable)

    phase 3 small molecule active

    1 trial

  23. EV/DNG (Qlaira, BAY86-5027)

    Bayer HealthCare AG

    Oral Contraceptive

    phase 3 small molecule completed

    1 trial

  24. EV/DNG (Qlaira, Natazia, BAY86-5027)

    Bayer HealthCare AG

    Metrorrhagia

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources